Dabur India posts Q3 FY24 consolidated PAT at Rs. 514.22 Cr
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Dabur India has reported total income of Rs. 3382.43 crores during the period ended December 31, 2023
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
The initiative is a response to the rising incidents of heart attacks and cardiac arrests in the state
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Granules India has reported total income of Rs. 1156.23 crores during the period ended December 31, 2023
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
Bayer has granted the non-exclusive rights to Sun Pharma to market and distribute a second brand of Finerenone under the brand name Lyvelsa
Microdosing has emerged as a key trend in the pharmaceutical and nutritional markets
A 'better for you' organic brand spanning Food & Beverages and Nutraceutical categories
Subscribe To Our Newsletter & Stay Updated